Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease

References

• Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3–19.
   PubMed Web of Science ®Google Scholar
• Baert L, Manfroi B, Casez O, et al. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. J Autoimmun. 2018;95:179–190.
   PubMed Web of Science ®Google Scholar
• Kampa M, Notas G, Stathopoulos EN, et al. The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer. Front Oncol. 2020;10:827.
   PubMed Web of Science ®Google Scholar
• La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol. 2013;148(3):322–327.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Steiner UC, Wuest B, et al. Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol. 2020;11:433–443.
   PubMedGoogle Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–263.
   PubMed Web of Science ®Google Scholar
• Smulski CR, Eibel H. BAFF and BAFF-Receptor in B cell selection and survival. Front Immunol. 2018;9:2285.
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201(1):35–39.
   PubMed Web of Science ®Google Scholar
• Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, et al. The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol. 2019;234(10):17050–17063.
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263–275.
   PubMed Web of Science ®Google Scholar
• Tsuji S, Cortesão C, Bram RJ, et al. TACI deficiency impairs sustained blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood. 2011;118(22):5832–5839.
   PubMed Web of Science ®Google Scholar
• Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 2016;25(6):582–592.
   PubMed Web of Science ®Google Scholar
• Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2):289–302.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32(5):1007–1011.
   PubMed Web of Science ®Google Scholar
• Qin Q, Chang Y, Wang D, et al. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis. Int Immunopharmacol. 2011;11(12):2167–2175.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang L, Wu Y, et al. Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA/1 mice. Eur J Pharmacol. 2011;654(3):304–314.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li P, Song S, et al. Comparative efficacy of TACI-Ig with TNF-alpha inhibitor and methotrexate in DBA/1 mice with collagen-induced arthritis. Eur J Pharmacol. 2013;708(1-3):113–123.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317(9):1270–1277.
   PubMed Web of Science ®Google Scholar
• González-Mendióroz M, Alvarez-Vázquez AB, Rubio-Martinez J. Structural analysis of the inhibition of APRIL by TACI and BCMA through molecular dynamics simulations. J Mol Graph Model. 2013;39:13–22.
   PubMed Web of Science ®Google Scholar
• Chen X, Hou Y, Jiang J, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis. Clin Pharmacokinet. 2014;53(11):1033–1044.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;56(8):948–959.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao Q, Hou Y, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):41–52.
   PubMed Web of Science ®Google Scholar
• Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021;159:105704.
   PubMed Web of Science ®Google Scholar
• Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39–54.
   PubMed Web of Science ®Google Scholar
• Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE disease activity score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78(3):365–371.
   PubMed Web of Science ®Google Scholar
• Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.
   PubMed Web of Science ®Google Scholar
• Ding J, Cai Y, Deng Y, et al. Telitacicept following plasma exchange in the treatment of subjects with recurrent NMOSD: study protocol for a single-center, single-arm, open-label study. Front Neurol. 2021;12:596791.
   PubMed Web of Science ®Google Scholar
• Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63(7):647–656.
   PubMed Web of Science ®Google Scholar
• Willen D, Uhl W, Wolna P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy caucasian and Japanese subjects. Eur J Drug Metab Pharmacokinet. 2020;45(1):27–40.
   PubMed Web of Science ®Google Scholar
• Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology. 2020;59(10):2930–2938.
   PubMed Web of Science ®Google Scholar
• Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B Cell-targeting agents. Front Med (Lausanne). 2020;7:303.
   PubMedGoogle Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–532.
   PubMed Web of Science ®Google Scholar